Sibutramine associated depression with suicide preoccupation: Two case reports

Abstract

Obesity which has medical morbidity and psychological components has an increasing prevalence rate. In recent years there is an increasing interest on pharmacological treatment of obesity. Sibutramine which was a -feniletilamine derivative had serotonergic, noradrenergic and weak dopaminergic reuptake inhibitor was approved by FDA in 1997 in treatment of obesity. In preclinical and clinical studies it was shown that sibutramine had antidepressant effects but this was beyond its antiobesity effects. In this presentation we present two cases of depression with suicidal ideation which was induced by a drug with antidepressant properties. We reviewed the psychiatric conditions due to sibutramine. It was aimed in this presentation to show relation between psychiatric symptoms and disorders with obesity and antiobesity drugs.